TY - JOUR
T1 - Quantitative measurement of breast carcinoma fibrosis for the prediction in the risk of bone metastasis
AU - Sun, Chong
AU - Wang, Bin
AU - Li, Jianmin
AU - Shangguan, Junjie
AU - Figini, Matteo
AU - Zhou, Kang
AU - Pan, Liang
AU - Ma, Quanhong
AU - Zhang, Zhuoli
N1 - Funding Information:
This research was generously supported by NIH NCI RO1CA196967 and NIH NCI RO1CA209886. Informed consent was obtained from all individual participants included in the study.
Funding Information:
This research was generously supported by NIH NCI RO1CA196967 and NIH NCI RO1CA209886.
Publisher Copyright:
© 2018, E-Century Publishing Corporation. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Background: Previous studies have shown the poor prognosis of metastatic breast cancer including bone metastasis. The early prediction and intervention of invasive breast carcinoma with bone metastasis are crucial to the outcomes of patients. The purpose of our study is to test the hypothesis that the collagen deposition of primary breast cancer can be used as a quantitative biomarker for the early prediction of bone metastasis. Methods: A total of sixty breast cancer patients were included in our study, and the surgical specimens of these patients were divided into three groups: patients with no metastasis (group 1), lymph node metastasis (group 2), and bone metastasis (group 3). Masson’s trichrome staining and hematoxylin and eosin staining were applied to all primary breast cancers. Collagen area percentage and tumor cell measurement of each sample were measured by HistoQuest software. Results: Measurement results of collagen area percentage (%) in primary breast tumors were 32.39 ± 13.30, 25.37 ± 11.10, and 22.71 ± 8.91 for groups 1, 2, and 3, respectively. The corresponding P values were 0.0779 (group 1 vs. group 2), 0.4086 (group 2 vs. group 3), and 0.0102 (group 1 vs. group 3). The correlation between collagen area percentage and tumor cell measurement were group 1 (P = 0.5927, r =-0.1273), group 2 (P = 0.5711, r =-0.1348), and group 3 (P = 0.0003, r =-0.7253). Conclusions: The collagen deposition of primary breast cancer can be used as a quantitative biomarker for the early prediction of bone metastasis.
AB - Background: Previous studies have shown the poor prognosis of metastatic breast cancer including bone metastasis. The early prediction and intervention of invasive breast carcinoma with bone metastasis are crucial to the outcomes of patients. The purpose of our study is to test the hypothesis that the collagen deposition of primary breast cancer can be used as a quantitative biomarker for the early prediction of bone metastasis. Methods: A total of sixty breast cancer patients were included in our study, and the surgical specimens of these patients were divided into three groups: patients with no metastasis (group 1), lymph node metastasis (group 2), and bone metastasis (group 3). Masson’s trichrome staining and hematoxylin and eosin staining were applied to all primary breast cancers. Collagen area percentage and tumor cell measurement of each sample were measured by HistoQuest software. Results: Measurement results of collagen area percentage (%) in primary breast tumors were 32.39 ± 13.30, 25.37 ± 11.10, and 22.71 ± 8.91 for groups 1, 2, and 3, respectively. The corresponding P values were 0.0779 (group 1 vs. group 2), 0.4086 (group 2 vs. group 3), and 0.0102 (group 1 vs. group 3). The correlation between collagen area percentage and tumor cell measurement were group 1 (P = 0.5927, r =-0.1273), group 2 (P = 0.5711, r =-0.1348), and group 3 (P = 0.0003, r =-0.7253). Conclusions: The collagen deposition of primary breast cancer can be used as a quantitative biomarker for the early prediction of bone metastasis.
KW - Bone metastasis
KW - Collagen deposition
KW - Early prediction
KW - Invasive breast carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85049311401&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049311401&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85049311401
SN - 1943-8141
VL - 10
SP - 1852
EP - 1859
JO - American Journal of Translational Research
JF - American Journal of Translational Research
IS - 6
M1 - AJTR0074054
ER -